Novus Partners with
Enlighten Interactive TV
to Bring its Cannabis MedPlan to the
Masses
Interactive Television Ads At
Point Of Sale Will Gather The Attention Of Cannabis
Consumers At The Right Time
Miami, FL --
June 25, 2018 -- InvestorsHub NewsWire
-- Novus Acquisition and
Development, Corp.
(OTC
Markets:
NDEV),
through its wholly owned subsidiary WCIG Insurance Services, Inc.,
is a diversified insurance entity in health, liability, annuity and
accident, and, the nation's first carrier/aggregator offering a
cannabis health plan, today
announced
its
business
collaboration recently announced is with Enlighten,
a
multifaceted cannabis technology company.
Novus
will
utilize Enlighten's
interactive
television
technologies
in
in a
revenue sharing deal. Enlighten will
place
Novus' message at the point of
sales in 650 dispensaries
across the country with advertising to engage and
educate
consumers
on
the Novus Cannabis
MedPlan. When
consumers
are engaged Novus will get analytics of
verified impressions from the consumer
mobile devices for retargeting.
Enlighten's
technology solutions
include interactive signage to inform and educate customers or
employees, a retail analytics portal, integrated technology
solutions to aggregate and systemize product offerings and internal
operations, and tailored marketing solutions for product
brands.
The company's
engagement focused approach helps its location partners match the
look and feel of modern technology-driven facilities, while
maintaining a unique identity, to educate its target audience and
increase revenue. Enlighten offers brands across the country with
the unique ability to reach a targeted demographic with engaging
advertisement right at the point of sale.
Novus' Chief
Executive Officer, Frank Labrozzi, commented, "We are thrilled to be
working with the team at Enlighten as they have built out
the first full
scale interactive
enterprise solution
in the cannabis space. Enlighten
is
already working with over 650 cannabis businesses,
including dispensaries,
cultivators, cannabis lounges
and medical facilities.
We believe our revolutionary medical cannabis health plan
will
greatly
benefit in becoming part of Enlighten's
network.
We continue to seek additional ways to increase our consumer
visibility and awareness in bringing reliable and affordable meds
to consumers
around
the nation."
About Enlighten
Enlighten, a full
spectrum enterprise solution managed by a team with a collective 20
years of experience serving Fortune 500 companies, first-class
retailers and top-end brands all over the world, brings cutting
edge retail technology to the cannabis industry.
With an
education forward approach, Enlighten helps its partners grow their
brand and build relationships with their customers through a
variety of solutions.
Its
technology solutions are intended to increase revenue and awareness
and keep customers engaged.
As an
aggregation of several notable companies from both inside and
outside of cannabis, Enlighten is one of the most
well-funded,
wide reaching and longest tenured companies in cannabis.
For more
information about Enlighten please visit getenlightened.io.
We invite you to do your due
diligence on Novus:
About Novus
Novus Acquisition
& Development Corp. (NDEV),
through its subsidiary WCIG Insurance, provides health insurance
and related insurance solutions within the wellness and medical
marijuana industries in states where legal programs exist. Novus
has developed its infrastructure within many lines of the insurance
business such as, health, property & casualty, life, accident
and fixed annuities.
Novus medical
cannabis benefits package will work as outside developers and will
not cultivate, handle, transport grow, extract, dispense, put up
for sale, put on the market, vend, deliver, supply, circulate, or
trade cannabis or any substances that violate the United States law
or the Controlled Substances Act, nor does it intend to do so in
the future and will continue to follow state and federal laws. The
statements made about specific products have not been evaluated by
the United States Food and Drug Administration (FDA) and are not
intended to diagnose, treat, cure or prevent disease. All
information provided on these press releases or any information
contained on or in any product label or packaging is for
informational purposes only and is not intended as a substitute for
advice from your physician or other health care professional. Once
a push notification is competed the transaction is solely between
the state-licensed dispensary and the registered
patient.
The state laws are in
conflict with the federal Controlled Substances Act. The current
administration has effectively stated that it is not an efficient
use of resources to direct federal law enforcement agencies to
prosecute those lawfully abiding by state designated laws, allowing
the use and distribution of medical marijuana. However, there is no
guarantee that the current administration, nor any future
administration, will not change this policy and decide to enforce
the federal laws strongly. Any such change in the federal
government's enforcement of current federal laws could cause
significant financial changes to Novus Medical Group. While we do
not intend to harvest, distribute or sell cannabis or cannabis
related products, we may be harmed by a change
in
enforcement by federal or state governments.
Forward-Looking Statements
This release includes
forward-looking statements, which are based on certain assumptions
and reflects management's current expectations. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations. Some of these factors
include: general global economic conditions; general industry and
market conditions and growth rates; uncertainty as to whether our
strategies and business plans will yield the expected benefits;
increasing competition; availability and cost of capital; the
ability to identify and develop and achieve commercial success; the
level of expenditures necessary to maintain and improve the quality
of services; changes in the economy; changes in laws and
regulations, includes codes and standards, intellectual property
rights, and tax matters; or other matters not anticipated; our
ability to secure and maintain strategic relationships and
distribution agreements. Novus Medical Group disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact Information
Corporate:
Chairman and
CEO
Frank
Labrozzi
frank@ndev.biz
855-228-7355
Investors:
Hayden
IR
hart@haydenir.com
917-658-7878
